Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

doi:10.1002/cncr.35343

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Cancer - 1 Sept 2024

Hatori Masahiro, Tsuji Daiki, Suzuki Kenichi, Yokokawa Takashi, Kawakami Kazuyoshi, Moriyama Ryo, Osada-Tsuchiya Marika, Otake Aki, Nakao Masahiko, Yano Takuya, Arakawa Yuichiro, Matsuo Keisuke, Ohashi Yasukata, Sakata Yasuhiko, Kogure Yuki, Tamaki Shinya, Wada Atsushi, Taki Yusuke, Sasahira Naoki, Ishii Hiroshi, Yamaguchi Masakazu, Itoh Kunihiko

Abstract excerpt

BACKGROUND: Genetic polymorphisms of molecules are known to cause individual differences in the therapeutic efficacy of anticancer drugs. However, to date, germline mutations (but not somatic mutations) for anticancer drugs have not been adequately studied. The objective of this study was to investigate the association between germline polymorphisms of gemcitabine metabolic and transporter genes with carbohydrate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CA-19-9 Antigen

Share to Deoxycytidine

Share to Gemcitabine

Share to Paclitaxel

Share to Pancreatic Neoplasms

Share to Pharmacogenomic Testing

Share to Ribonucleoside Diphosphate Reductase

Source

Open in PubMed

Identifiers

PMID: 38682652
DOI: 10.1002/cncr.35343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).PMID 38682652Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.Semantic proximity Read ↗

Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.Semantic proximity Read ↗

Impact of genetic factors on platinum-induced gastrointestinal toxicity.Semantic proximity Read ↗

Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.Semantic proximity Read ↗

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.Semantic proximity Read ↗

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.